Dear Safar Friends and Family, In honor of Tuesday’s International Day of the Girl, I wanted to reach out to the Safar family to share the poignant and important message from President and Mrs. Obama. Safar champions women from all walks of life, and we are proud to support innovative and impactful female-led companies. All my Best, Nader Motamedy #internationaldayofthegirl https://lnkd.in/eUY_jJAd
Safar Partners
Venture Capital and Private Equity Principals
Cambridge, Massachusetts 1,049 followers
Our mission is to invest in founders solving the world's most pressing issues.
About us
Safar Partners is a seed- to growth-stage venture fund investing primarily in technology companies out of MIT, Harvard, and the University of Rochester. We invest in platform technologies in the cleantech and advanced materials, AI/IT and robotics, and life science/medical device areas.
- Website
-
https://www.safar.partners
External link for Safar Partners
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 2-10 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
- Founded
- 2019
Locations
-
Primary
Get directions
1 Broadway
Cambridge, Massachusetts 02142, US
Employees at Safar Partners
Updates
-
Safar Partners reposted this
Immensely proud of our team and collaborators for reaching this milestone!
C2Sense® and Princeton BioMeditech Receive Second Award from NIH RADx® Tech High Performance Program for Digitally Connected, At-Home Diagnostic Reader and Multiplex COVID-19/Flu A&B Rapid Test WATERTOWN, Mass. and MONMOUTH JUNCTION, N.J., April 9, 2024 /PRNewswire/ -- C2Sense, Inc., experts in advanced optical sensing platforms and Princeton BioMeditech Corporation (PBM), a world leader in rapid, point-of-care (POC) diagnostics, announced today that they have secured a second National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech High Performance award. The companies are currently planning their upcoming clinical trial, regulatory submission, and transfer to manufacture. "After rigorous testing and intensive data collection, Halo®, used in conjunction with the PBM multiplex rapid test, continues to demonstrate outstanding sensitivity and reliability," said Jason Cox, Ph.D., CEO at C2Sense. "Powered by our latest algorithm release, the price vs. performance of our Halo reader is unparalleled." Testing was conducted by the Atlanta Center for Microsystems-Engineered Point-of-Care Technologies (ACME POCT) on behalf of RADx using SARS-CoV-2 (Omicron variant) and Flu A&B viral samples. Visit https://lnkd.in/eYz-wFd6 for more! #FluB # FluA #COVID19 #RADx #RADxTech #NIH #Flu #LFA #Immunoassay #RapidTest #DigitalDiagnostics #AtHomeDiagnostics #testing #digitaltesting #multiplex
-
-
Safar Partners reposted this
Do you have a unique product or innovation you believe will enable future semiconductors? Don’t miss the opportunity to showcase it during our 3rd Lam Capital Venture Competition. Selected startups will pitch to a panel of distinguished judges for the chance to receive a $250,000 investment from Lam Capital. We are thrilled to have Intel Corporation's Jennifer Ard, CFA, SK hynix's Rene Do, Playground Global's Matt Hershenson, BRV Capital Management's David Lam, Safar Partners' Vera Schroeder, d-Matrix's Sid Sheth, M12, Microsoft's Venture Fund's Michael Stewart, and more joining us as investors and speakers this year. The deadline for submissions is Monday, April 15—apply now! https://bit.ly/3SL2zHW
-
-
We are excited to share a milestone for Pirouette, a groundbreaking company in injectable medicine where Safar is a proud investor. They have been selected for the prestigious NIH I-Corps Program. Pirouette is on a mission to simplify and increase access to life-saving injections. Pirouette CEO, @Conor Cullinane, and his powerhouse team from Harvard Medical, HBS, MIT, NASA, & GE are set to transform the $600B injections market. Learn more and invest alongside us → https://lnkd.in/gJmSPQFM. Let’s make life-saving injections accessible for all, together!
Pirouette Medical (YC S21) makes injections as easy as pushing a button. They've just been accepted into the National Institutes of Health (NIH) I-Corps Program, recognized for their innovative approach to combating the opioid crisis with their novel Naloxone Auto-Injector! I-Corps participation furthers Pirouette's progress as a Phase I SBIR Awardee. This program supplements their original award with an additional $55,000 grant to advance Pirouette's mission, ensuring the Naloxone Auto-Injector can reach those who need it. Over the next two months, Pirouette will fine-tune their commercialization strategy, and ensure their product meets market needs.
RePORT 〉 RePORTER
reporter.nih.gov